Press Releases

Press Releases

    Date Title View
    12/22/16
    Summary ToggleHorizon Pharma plc Announces the U.S. Patent and Trademark Office Issuance of an Additional Notice of Allowance With Claims Covering RAVICTI® (glycerol phenylbutyrate) Oral Liquid
    12/22/16
    Summary ToggleHorizon Pharma plc to Present at the 35th Annual J.P. Morgan Healthcare Conference
    12/22/16
    Summary ToggleHorizon Pharma plc Announces Availability of QUINSAIR™ (levofloxacin inhalation solution) in Canada for the Treatment of Specific Lung Infections in Adults with Cystic Fibrosis
    12/08/16
    Summary ToggleHorizon Pharma plc to Participate in Investor Conference in December
    12/08/16
    Summary ToggleHorizon Pharma plc Announces Topline Results from Phase 3 Study of  ACTIMMUNE® (interferon gamma-1b) in Friedreich's Ataxia
    11/14/16
    Summary ToggleHorizon Pharma plc Presents Data on KRYSTEXXA® (pegloticase) for the Management of Refractory Chronic Gout at the 2016 ACR/ARHP Annual Meeting
    11/11/16
    Summary ToggleHorizon Pharma plc Selected as One of Chicago Tribune's 2016 Top Workplaces
    11/07/16
    Summary ToggleHorizon Pharma plc Announces Third-Quarter 2016 Financial Results
    11/04/16
    Summary ToggleHorizon Pharma plc to Participate in Investor Conferences in November
    11/03/16
    Summary ToggleHorizon Pharma plc Announces Availability of RAVICTI® (glycerol phenylbutyrate) Oral Liquid in Canada
    Displaying 1 - 10 of 51 results